BACKGROUND: Galectin-3 (Gal-3) as a biomarker of fibrosis and inflammation has been implicated in the development and progression of heart failure (HF) and may predict increased morbidity and mortality in society. OBJECTIVES: In this preliminary report we investigated the utility of a novel serum marker for the diagnosis of acute HF (AHF). MATERIAL AND METHODS: The study involved 14 AHF patients aged 67.0 ± 14.6 yrs. with left ventricular ejection fraction (LVEF) 29.29 ± 10.73%, hospitalized at the Intensive Coronary Care Unit, where the research took place. In addition, a control group consisting of 19 volunteers who were age, gender and ethnically matched to the HF group was recruited. In the study group, the concentrations of Gal-3, NT-proBNP, hsCRP and basic clinical parameters, such as prevalence of dyspnea and LVEF were determined. The concentration of Gal-3 in serum was examined by an automated quantitative test (VIDAS® Galectin-3, bioMerieux SA, France) using the ELFA technique. The survival rate was assessed after a 12-month follow-up. RESULTS: The median (IQR) Gal-3 concentrations in patients with AHF were higher (nearly 2.1-times) than in the control group - 17.8 (10.3-27.8) ng/mL vs. 8.4 (6.5-11.0) ng/mL; p = 0.0007. In our study group, the median (IQR) of concentrations of NT-proBNP 4723 (1415-29725) pg/mL and hsCRP 10.0 (4.9-13.9) mg/L were observed. In those patients, the statistically significant correlation (Spearman's rank-correlation coefficient) between the concentrations of Gal-3 and NT-proBNP (Rs = 0.565; p = 0.035) as well as the value of LVEF and the concentration of hsCRP (Rs = -0.663; p = 0.020) were stated. The serum Gal-3 concentrations were significantly higher among the 4 HF patients (28.6%) who had died than among the HF patients who were alive after this time (n = 10) (55.6 ± 37.6 ng/mL vs. 15.0 ± 7.04 ng/mL; p = 0.005). CONCLUSIONS: Higher expression of Gal-3 is an indicator of myocardial fibrosis and remodeling in decompensated HF. Therefore, galectin-3 seems to be an interesting and valuable marker of AHF.
BACKGROUND:Galectin-3 (Gal-3) as a biomarker of fibrosis and inflammation has been implicated in the development and progression of heart failure (HF) and may predict increased morbidity and mortality in society. OBJECTIVES: In this preliminary report we investigated the utility of a novel serum marker for the diagnosis of acute HF (AHF). MATERIAL AND METHODS: The study involved 14 AHF patients aged 67.0 ± 14.6 yrs. with left ventricular ejection fraction (LVEF) 29.29 ± 10.73%, hospitalized at the Intensive Coronary Care Unit, where the research took place. In addition, a control group consisting of 19 volunteers who were age, gender and ethnically matched to the HF group was recruited. In the study group, the concentrations of Gal-3, NT-proBNP, hsCRP and basic clinical parameters, such as prevalence of dyspnea and LVEF were determined. The concentration of Gal-3 in serum was examined by an automated quantitative test (VIDAS® Galectin-3, bioMerieux SA, France) using the ELFA technique. The survival rate was assessed after a 12-month follow-up. RESULTS: The median (IQR) Gal-3 concentrations in patients with AHF were higher (nearly 2.1-times) than in the control group - 17.8 (10.3-27.8) ng/mL vs. 8.4 (6.5-11.0) ng/mL; p = 0.0007. In our study group, the median (IQR) of concentrations of NT-proBNP 4723 (1415-29725) pg/mL and hsCRP 10.0 (4.9-13.9) mg/L were observed. In those patients, the statistically significant correlation (Spearman's rank-correlation coefficient) between the concentrations of Gal-3 and NT-proBNP (Rs = 0.565; p = 0.035) as well as the value of LVEF and the concentration of hsCRP (Rs = -0.663; p = 0.020) were stated. The serum Gal-3 concentrations were significantly higher among the 4 HF patients (28.6%) who had died than among the HF patients who were alive after this time (n = 10) (55.6 ± 37.6 ng/mL vs. 15.0 ± 7.04 ng/mL; p = 0.005). CONCLUSIONS: Higher expression of Gal-3 is an indicator of myocardial fibrosis and remodeling in decompensated HF. Therefore, galectin-3 seems to be an interesting and valuable marker of AHF.
Authors: Vijayendran Chandran; Kun Gao; Vivek Swarup; Revital Versano; Hongmei Dong; Maria C Jordan; Daniel H Geschwind Journal: Elife Date: 2017-12-19 Impact factor: 8.140
Authors: Pedro Caravaca Perez; José R González-Juanatey; Jorge Nuche; Lucia Matute-Blanco; Isabel Serrano; Manuel Martínez Selles; Rafael Vázquez García; Luis Martínez Dolz; Manuel Gómez-Bueno; Domingo Pascual Figal; María G Crespo-Leiro; Álvaro García-Osuna; Jordi Ordoñez-Llanos; Juan Cinca Cuscullola; José M Guerra; Juan F Delgado Journal: Front Cardiovasc Med Date: 2022-04-07
Authors: Sai Polineni; Devin M Parker; Shama S Alam; Heather Thiessen-Philbrook; Eric McArthur; Anthony W DiScipio; David J Malenka; Chirag R Parikh; Amit X Garg; Jeremiah R Brown Journal: J Am Heart Assoc Date: 2018-07-07 Impact factor: 5.501
Authors: Agata Tymińska; Agnieszka Kapłon-Cieślicka; Krzysztof Ozierański; Monika Budnik; Anna Wancerz; Piotr Sypień; Michał Peller; Paweł Balsam; Grzegorz Opolski; Krzysztof J Filipiak Journal: Dis Markers Date: 2019-10-10 Impact factor: 3.434